Inhalation Sedatives Global Market Report 2024

The inhalation sedatives market size has grown steadily in recent years. It will grow from $2.24 billion in 2023 to $2.34 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of chronic diseases requiring sedation during treatment, a growing geriatric population that often necessitates sedatives for medical procedures, heightened awareness and recognition of the benefits of inhalation sedatives among healthcare professionals and patients, augmented investments in research and development to enhance these medications, the expansion of pipelines for new inhalation sedatives, and an overall increase in surgical procedures where sedation is a crucial component. These elements collectively contributed to the growth and adoption of inhalation sedatives during that time.

The inhalation sedatives market size is expected to see steadily grown in the next few years. It will grow to $2.88 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. Anticipated growth in the forecast period is expected to stem from various factors, including the increasing demand for outpatient procedures that often require sedation, advancements in anesthesia delivery systems enhancing sedation practices, the integration of telemedicine and remote monitoring solutions in sedation management, a growing prevalence of respiratory disorders necessitating sedatives for treatment, and the expansion of ambulatory surgery centers where sedation plays a crucial role in procedures.

The swift action and brief duration of inhalation sedatives are anticipated to propel the inhalation sedative market. Their rapid onset and quick recovery make them suitable for short medical procedures, notably in pediatric dental surgeries and intensive care units for pain management and rapid recuperation. Nitrous oxide, the commonly used inhalation sedative, typically administered as a 30-70% oxygen mix, takes 1-2 minutes to act and lasts for about 5 minutes. Its quick action and short duration make it the preferred sedative for dental treatments, thereby driving the demand for inhalation sedatives due to their rapid efficacy.

The rising incidence of respiratory ailments is expected to drive the future growth of inhalation sedatives. These medical conditions impact the respiratory system, including the lungs and associated passages. Inhalation sedatives play a pivotal role in managing respiratory diseases by addressing various objectives, from reducing anxiety to improving patient comfort and assisting in medical procedures. In 2021, Australia witnessed around 6,551 deaths, representing 27.1% of all deaths, attributed to chronic respiratory conditions, notably chronic obstructive pulmonary disease (COPD), accounting for 2.6% of these deaths. Hence, the increasing prevalence of respiratory illnesses is poised to fuel the demand for inhalation sedatives in the market. A new trend in the inhalation sedative market is the production of generic variants. Generics are formulations replicating patented drugs in composition, dose, and effect once the patent expires. The surge in generic inhalation sedative production has been notable. For instance, Hikma Pharmaceuticals PLC launched KLOXXADOTM (naloxone hydrochloride) in August 2021, offering an inhalation spray designed for immediate treatment of opioid overdose, containing twice the amount of naloxone per spray compared to Narcan Nasal Spray. This shift towards generic inhalation sedatives is expected to become a prominent trend, shaping the inhalation sedative market.

Leading companies in the inhalation sedative sector are innovating to meet the burgeoning demand for inhaled sedation. Products like Sedaconda (isoflurane) are being developed to cater to this need, particularly in Germany. Sedaconda serves as a prescription sedative for mechanically ventilated adult patients in intensive care, representing the first approved inhaled sedation therapy for this demographic. Sedana Medical AB introduced Sedaconda (isoflurane) in February 2022, offering an inhaled sedation therapy that integrates with existing workflows in intensive care units through the Sedaconda ACD (Anaesthetic Conserving Device), ensuring safe and effective delivery of inhaled sedation.

Major companies operating in the inhalation sedatives market include AbbVie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Lunan Pharmaceutical Group Co. Ltd., Novartis International AG, Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Torrent Pharmaceuticals Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Ltd., Wockhardt Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Jubilant Life Sciences Limited.

North America was the largest region in the inhalation sedatives market in 2023. The regions covered in the inhalation sedatives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the inhalation sedatives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The inhalation sedatives market consists of sales of halothane, fluticasone, budesonide, and ciclesonide. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary products in the inhalation sedatives market include sevoflurane, desflurane, isoflurane, and nitrous oxide. Sevoflurane, for instance, is a nonflammable, highly fluorinated methyl isopropyl ether with a sweet scent, often employed as an inhalational anesthetic for both the induction and maintenance of general anesthesia. These sedatives find applications in various procedures such as induction and maintenance across different healthcare sectors, including hospitals, ambulatory surgical centers, and other medical facilities where anesthesia is required.

The inhalation sedatives market research report is one of a series of new reports provides inhalation sedatives market statistics, including inhalation sedatives industry global market size, regional shares, competitors with inhalation sedatives market share, detailed inhalation sedatives market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation sedatives industry. This inhalation sedatives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.